Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

Abstract

HRD occurs in endometrial cancers and is largely restricted to non-endometrioid, <i>TP53</i>-mutant endometrial cancers. Evaluation of HRD may help select patients that could benefit from treatments targeting this defect, including platinum compounds and PARP inhibitors.